Patient organisations 'too influenced by corporate funders'
Researchers have called for action to safeguard the independence of patient advocacy organisations as they increasingly rely on pharma funding.
London-listed Poolbeg discussing Hookipa merger
The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.
CARsgen gets a win for CAR-T in solid tumours
CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.
Regeneron builds in eye disease tech with Oxular takeover
Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
hubXchange returns with its latest series of roundtables!
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
Welcome to the Bacteriophage Therapy Summit!
Combating Antibiotic Resistance with Effective & Sustainable Phage-Based Therapies
Biotech Showcase marking 17 years of innovation and opportun...
Biotech Showcase is a cornerstone of the life science industry, with a 17-year history of connecting private and micro- to mid-cap biotech companies with top-tier investors and biopharmaceu